Gene Liau is VP at Stoke Therapeutics, Inc. (STOK). They have made 5 open-market trades across 1 company since 2020, most recently 2021-03-02.
CIK 0001780082
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| STOK | 21,351 | $517K |
Shares reported on the most recent Form 4, priced at the 2021-03-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| STOK | SELL | 2020-12-28 | 2021-03-04 | $62.79 | $480K | -12.9% | -31.4% | -33.3% |
| STOK | SELL | 2020-10-16 | 2020-10-20 | $38.20 | $1.7M | +0.4% | +6.7% | +82.7% |
| STOK | SELL | 2020-10-13 | 2020-10-13 | $40.00 | $66K | +2.0% | +12.1% | +48.3% |
| STOK | SELL | 2020-06-01 | 2020-06-03 | $26.32 | $1.0M | -11.4% | -12.6% | +8.3% |
| STOK | SELL | 2020-05-22 | 2020-05-26 | $30.00 | $225K | -6.9% | -11.1% | +6.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.